| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 09/16/2008 | CA2120732C Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the cd2/lfa-3 interaction |
| 09/12/2008 | WO2008109856A2 Methods of using diazepinone compounds in treating sodium channel-mediated diseases or conditions |
| 09/12/2008 | WO2008109829A1 Cyclopamine lactam analogs and methods of use thereof |
| 09/12/2008 | WO2008109818A1 Treating cancer with granulocyte-macrophage colony stimulating factor |
| 09/12/2008 | WO2008109740A2 Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers |
| 09/12/2008 | WO2008109737A1 Substituted phenoxy aminothiazolones as estrogen related receptor-alpha modulators |
| 09/12/2008 | WO2008109727A1 Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
| 09/12/2008 | WO2008109614A1 9-chloro noscapine and its use in treating cancers, including drug-resistant cancers |
| 09/12/2008 | WO2008109613A1 Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors |
| 09/12/2008 | WO2008109599A1 Pyrimido [5,4-c] quinoline-2, 4-diamine derivatives and methods of use thereof |
| 09/12/2008 | WO2008109382A1 Nucleic acid compounds for inhibiting pkn3 gene expression and uses thereof |
| 09/12/2008 | WO2008109376A1 Nucleic acid compounds for inhibiting bcr-abl gene expression and uses thereof |
| 09/12/2008 | WO2008109365A1 Nucleic acid compounds for inhibiting raf1 gene expression and uses thereof |
| 09/12/2008 | WO2008109361A1 Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
| 09/12/2008 | WO2008109360A1 Taxane analogs for the treatment of brain cancer |
| 09/12/2008 | WO2008109352A2 Nucleic acid compounds for inhibiting akt gene expression and uses thereof |
| 09/12/2008 | WO2008109163A1 Nanoparticle comprising rapamycin and albumin as anticancer agent |
| 09/12/2008 | WO2008109027A2 Tri-aryl/heteroaroaromatic cannabinoids and use thereof |
| 09/12/2008 | WO2008109005A2 Use of anti-cd22 immunotoxins and protein-synthesis-inhibiting chemotherapeutic agents in treatment of b cell cancers |
| 09/12/2008 | WO2008108986A2 Methods and compositions for treating tumor diseases |
| 09/12/2008 | WO2008108910A2 Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy |
| 09/12/2008 | WO2008108679A1 Tumor vaccine, a method for producing a tumor vaccine and a method for carrying out antitumor immunotherapy |
| 09/12/2008 | WO2008108647A2 Enhancement of anticancer therapy by flavonoids |
| 09/12/2008 | WO2008108386A1 Pharmaceutical composition |
| 09/12/2008 | WO2008108257A1 Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them |
| 09/12/2008 | WO2008107873A1 Mercaptopurine derivatives as anticancer agents |
| 09/12/2008 | WO2008107471A2 Modified hydroxypolymer conjugates with killing effect on tumor cells |
| 09/12/2008 | WO2008107322A1 Indole, benzimidazole or benzotriazole derivatives including a piperidine or piperazine core as anti-neoplasic agents or cell proliferation inhibitors |
| 09/12/2008 | WO2008107176A1 Meta-substituted phenyl sulfonyl amides of secondary amino acid amides, the production thereof, and use thereof as matriptase inhibitors |
| 09/12/2008 | WO2008106803A1 Double-stranded locked nucleic acid compositions |
| 09/12/2008 | WO2008106796A1 Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity |
| 09/12/2008 | WO2008106781A1 Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy |
| 09/12/2008 | WO2008106731A1 A target for breast cancer therapy and/or diagnosis |
| 09/12/2008 | WO2008106721A1 Compositions and methods for delivery of anti-cancer agents |
| 09/12/2008 | WO2008089105A3 Antiviral nucleoside analogs |
| 09/12/2008 | WO2008080623A3 Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo |
| 09/12/2008 | WO2008072952A3 Anti-inflammatory compounds containing compositions for treatment of cancer |
| 09/12/2008 | WO2008070016A3 Inhibitors of akt activity |
| 09/12/2008 | WO2008057994A3 Pyrrolotriazine kinase inhibitors |
| 09/12/2008 | WO2008049990A3 Use of an anti-cd151 antibody in the treatment of cancer |
| 09/12/2008 | WO2007134678A3 Triazole derivatives ii |
| 09/12/2008 | WO2007107594A3 Six-membered heterocycle substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors |
| 09/12/2008 | WO2007089945A3 Treating diseases by targeting silt3 |
| 09/12/2008 | CA2680212A1 Substituted phenoxy aminothiazolones as estrogen related receptor-.alpha. modulators |
| 09/12/2008 | CA2680161A1 Pharmaceutical composition |
| 09/12/2008 | CA2680060A1 Double-stranded locked nucleic acid compositions |
| 09/12/2008 | CA2680058A1 Induction of apoptosis and inhibition of cell proliferation through modulation of carnitine palmitoyltransferase 1c activity |
| 09/12/2008 | CA2679960A1 Modified hydroxypolymer conjugates with killing effect on tumor cells |
| 09/12/2008 | CA2679944A1 Substituted phenoxy thiazolidinediones as estrogen related receptor-alpha modulators |
| 09/12/2008 | CA2679919A1 Compositions and methods for delivery of anti-cancer agents |
| 09/12/2008 | CA2679845A1 Cyclopamine lactam analogs and methods of use thereof |
| 09/12/2008 | CA2679757A1 Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof |
| 09/12/2008 | CA2679700A1 Mercaptopurine derivatives as anticancer agents |
| 09/12/2008 | CA2679548A1 Methods and compositions for treating tumor diseases |
| 09/12/2008 | CA2679387A1 Nucleic acid compounds for inhibiting akt gene expression and uses thereof |
| 09/12/2008 | CA2679103A1 O6-alkylguanine-dna alkyltransferase inactivators |
| 09/12/2008 | CA2679045A1 Cancer antigen-specific t-cell receptor gene, peptide encoded by the gene, and use of them |
| 09/12/2008 | CA2678555A1 Amelioration of cellular stress response |
| 09/11/2008 | US20080221309 MN Gene and Protein |
| 09/11/2008 | US20080221308 HDAC9 polypeptides and polynucleotides and uses thereof |
| 09/11/2008 | US20080221221 Application of 2-bromide-isovanillin for the manufacture of a medicament for anti-cancer or/and radiation/chemotherapy sensitization |
| 09/11/2008 | US20080221207 Use of specific cyklolignans |
| 09/11/2008 | US20080221202 treatment of disorders and conditions modulated by at least one progesterone or glucocorticoid receptor; 11-(4-Dimethylamino-phenyl)-1-hydroxy-12a-methyl-1-prop-1-ynyl-1,3,4,4a,4b,5,6,9,10,11,12,12a-dodecahydro-2-oxa-chrysen-8-one |
| 09/11/2008 | US20080221201 4-(5-cyano-1-methyl-1H-pyrrol-2-yl)-N-methylbenzenesulfonamide; contraception, treating or preventing fibroids, uterine leiomyomata, endometriosis, dysfunctional bleeding, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake |
| 09/11/2008 | US20080221181 Compounds for treating tumors |
| 09/11/2008 | US20080221179 SUBSTITUTED PHENOXY AMINOTHIAZOLONES as estrogen related receptor-alpha modulators |
| 09/11/2008 | US20080221178 Benzimidazole Derivatives,Compositions Containing Them, Preparation Thereof and Uses Thereof |
| 09/11/2008 | US20080221163 behave as estrogen antagonists in the uterus that do not stimulate the ovaries; for treating endometriosis and uterine leiomyoma; 8-Methylsulfanyl-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl-5H-6-oxa-chrysen-2-ol hydrochloride |
| 09/11/2008 | US20080221160 Sulfonylated heterocycles useful for modulation of the progesterone receptor |
| 09/11/2008 | US20080221148 Compounds and methods for kinase modulation, and indications therefor |
| 09/11/2008 | US20080221146 Inhibit the multimerization of nucleophosmin; cancer |
| 09/11/2008 | US20080221138 Method of using SAHA and Erlotinib for treating cancer |
| 09/11/2008 | US20080221135 Combination therapy |
| 09/11/2008 | US20080221131 Respiratory system disorders; asthma; chronic obstructive pulminary disease; antiproliferative agents; immunosuppressants |
| 09/11/2008 | US20080221126 N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and bortezomib effect apoptosis of myeloma cells; optimal precision in concentration yields efficacy without toxicity, requires a regimen based on kinetics of the active ingredients' availability to target sites |
| 09/11/2008 | US20080221125 Novel heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| 09/11/2008 | US20080221124 Cancer drug; due to high solubility of ethanolamine salt in the aqueous phase of reaction mixture, it can be separated from the organic phase with little, no loss of yield; aqueous phase can be charged to hot aqueous acetic acid to crystallize product; poorly filtering polymorphic form is not generated |
| 09/11/2008 | US20080221123 geranylgeranyltransferase I inhibitors; treatment of neoplasia, hyperproliferative cell growth, psoriasis, intimal hyperplasia (restinosis) and chronic inflammatory diseases including rheumatoid and osteoarthritis |
| 09/11/2008 | US20080221122 cancer and non-cancer diseases associated with vascular proliferation; mitoxantrone resistant, taxol resistant cancers |
| 09/11/2008 | US20080221119 Pyrrolo-pyridine kinase modulators |
| 09/11/2008 | US20080221118 Tetrahydroquinoline Derivatives |
| 09/11/2008 | US20080221102 Composition and methods for modulating a kinase cascade |
| 09/11/2008 | US20080221099 Dihydropteridinones for the treatment of cancer diseases |
| 09/11/2008 | US20080221086 Novel Inhibitors of Glutaminyl Cyclase |
| 09/11/2008 | US20080221082 of the alpha V beta 3 integrin receptor; , thromboembolic events, cardiovascular disorders, lung diseases, disorders of the CNS, the kidney, the gastrointestinal tract or inflammation |
| 09/11/2008 | US20080221080 Method of Treating Mixed Lineage Leukemia Gene-Rearranged Acute Lymphoblastic Leukemias |
| 09/11/2008 | US20080221077 Ansamycin formulations and methods of use thereof |
| 09/11/2008 | US20080221069 Novel Therapeutic Agents for the Treatment of Cancer, Metabolic Diseases and Skin Disorders |
| 09/11/2008 | US20080221068 Oral administration of an amino acid with a N-terminal blocking group and a N-(2-boric pyrrolyl) group attached to the carboxyl group; anticarcinogenic, antiproliferative, antimetastasis agents for lung, kidney, pancreatic, breast, and colorectal cancers; angiogenesis inhibition |
| 09/11/2008 | US20080221065 Pharmaceutical formulations; epothilone and mannitol or a cyclodextrin parenteral administration in the form of an infusion concentrate or lyophilised composition |
| 09/11/2008 | US20080221061 Lung-Targeted Drugs |
| 09/11/2008 | US20080221060 Therapeutic Compounds |
| 09/11/2008 | US20080221058 Tumor-Specific Vector for Gene Therapy |
| 09/11/2008 | US20080221056 Early Detection and Prognosis of Colon Cancers |
| 09/11/2008 | US20080221054 In vitro; transgenic cells, mammals; kits |
| 09/11/2008 | US20080221040 Compositions and Methods for the Control of Mammary Cell Number |
| 09/11/2008 | US20080221036 Use of AGT and its derivatives for manufacturing anti-angiogenesis pharmaceutical compositions |
| 09/11/2008 | US20080221014 Method of Diagnosing and Treating Glioma |
| 09/11/2008 | US20080220500 Expression vector comprising nucleotide sequences coding lipogenic enzyme for treatment and prevention of cardiovascular, inflammatory, nervous system, gastrointestinal and psychological disorders |
| 09/11/2008 | US20080220455 p53-DEPENDENT APOPTOSIS-INDUCING PROTEIN AND METHOD OF SCREENING FOR APOPTOSIS REGULATOR |